Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE1831 in Immunoglobulin G4-Related Disease
NCT07061938Phase 2Recruiting
- Sponsor
- Acepodia
- Start
- Jan 2026
- Primary completion
- Sep 2029
- Modality
- Antibody-Drug Conjugates (ADCs), Native Immune Cells
- Countries
- 3
01
Overview
Phase 2, open-label trial of ACE1831 in immunoglobulin G4-related disease (IgG4-RD) (2 arms), sponsored by Acepodia. Primary endpoint: Safety and Tolerability of ACE1831 as Assessed by Adverse Events, Clinical Laboratory Tests, Physical Examinations, ECGs, and Vital Signs at 72 weeks. Started Jan 2026; status: recruiting.
02
Drugs
ACE1831
03
Conditions
immunoglobulin G4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT07061938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061938.